Lyonbiopole congratulates two of its members, Axoltis and Advanced Biodesign, who were honored on November 7 at the Galien USA Awards, where they were nominated in the « Best StartUp » category.

 » Axoltis Pharma’s team is very proud to be among the hashtag#PrixGalien USA Award nominees for « Best Startup » ! 

Our lead innovative product, NX210c, could change the game in the treatment of neurodegenerative diseases thanks to its properties, especially the recovery of the blood brain barrier integrity which is impaired in a broad range of diseases. We received the authorization to launch a phase II clinical trial in Amyotrophic Lateral Sclerosis (ALS), where the BBB is impaired since the early stages of the disease.

Axoltis collaborates with several academic labs and companies in the world, especially in North America to explore all the potential indications and properties of NX210c. « 

LinkedIn Post

« We are thrilled to announce that Advanced Biodesign has been nominated as the “Best Start-Up” at the prestigious Prix Galien USA 2024! 🏆
This nomination is a testament to our unwavering commitment to innovation and pushing the boundaries of biotechnology. It reflects the hard work and passion of our entire team in improving health and well-being through cutting-edge biotechnological solutions.

A huge thank you to all our partners, clients, and supporters for their trust and unwavering support. Together, we continue to turn innovative ideas into life-changing realities. »

LinkedIn Post